TP53 Mutation Characteristics and Their Effects on Overall Survival in AML and MDS

被引：0
|
作者：
Puzo, Christian [1 ]
Hager, Karl [1 ]
Rinder, Henry [1 ]
Weinberg, Olga [2 ]
Siddon, Alexa [1 ]
机构：
[1] Yale Sch Med, New Haven, CT USA
[2] UT Southwestern Med Ctr, Dallas, TX USA
来源：
LABORATORY INVESTIGATION | 2024年 / 104卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
1180
引用
收藏
页码：S1468 / S1470
页数：3
相关论文
共 50 条
  • [21] Molecular Characterization and Clinical Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Patients With TP53 Mutation
    Li, Yanfen
    Wan, Hua
    Jing, Yu
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (12): : 841 - 851
  • [22] Reply to Goel et al. ‘TP53 mutation allele-burden and disease outcome in MDS/AML’
    D A Sallman
    R Komrokji
    A List
    E Padron
    Leukemia, 2017, 31 : 767 - 768
  • [23] Reply to Goel et al. 'TP53 mutation allele- burden and disease outcome in MDS/AML'
    Sallman, D. A.
    Komrokji, R.
    List, A.
    Padron, E.
    LEUKEMIA, 2017, 31 (03) : 767 - 768
  • [24] Clinical Characteristics and Overall Survival Among Acute Myeloid Leukemia (AML) Patients with TP53 Gene Mutation (TP53m) or Chromosome 17p Deletion (17p del)
    Daver, Naval
    Iqbal, Shahed
    Huang, Julie
    Renard, Camille
    Lin, Joyce
    Pan, Harry
    Xing, Guan
    Pan, Yang
    Ramsingh, Giri
    BLOOD, 2022, 140 : 1445 - 1446
  • [25] Analysis of therapy-related MDS/AML identifies somatic mutations in nearly all samples and shorter survival associated with TP53 loss or mutation
    Shih, A.
    Chung, S. S.
    Abdel-Wahab, O.
    Dolezal, E. K.
    Park, C. Y.
    Nimer, S. D.
    Levine, R. L.
    Klimek, V. K.
    LEUKEMIA RESEARCH, 2013, 37 : S148 - S149
  • [26] Isolated TP53 Mutations Portend Worse Prognosis in MDS and AML Compared to TP53 Mutations with Concurrent Myeloid-Associated Mutations
    Hussaini, Mohammad
    Abuel-Haija, Mohammad
    Padron, Eric
    David, Sallman
    Song, Jinming
    MODERN PATHOLOGY, 2018, 31 : 524 - 525
  • [27] Isolated TP53 Mutations Portend Worse Prognosis in MDS and AML Compared to TP53 Mutations with Concurrent Myeloid-Associated Mutations
    Hussaini, Mohammad
    Abuel-Haija, Mohammad
    Padron, Eric
    David, Sallman
    Song, Jinming
    LABORATORY INVESTIGATION, 2018, 98 : 524 - 525
  • [28] Distinct Implications of TP53 Hits for Patients with Treatment-Related MDS and AML
    Kuzmanovic, Teodora
    Patel, Bhumika J.
    Nagata, Yasunobu
    Awada, Hassan
    Hirsch, Cassandra M.
    Przychodzen, Bartlomiej P.
    Sanikommu, Srinivasa Reddy
    Williams, Louis
    Mukherjee, Sudipto
    Advani, Anjali S.
    Nazha, Aziz
    Gerds, Aaron T.
    Radivoyevitch, Tomas
    Carraway, Hetty E.
    Sekeres, Mikkael A.
    Maciejewski, Jaroslaw P.
    BLOOD, 2018, 132
  • [29] Mutation and function of TP53
    Milner, J
    BRAIN PATHOLOGY, 2000, 10 (04) : 504 - 504
  • [30] Gene Amplifications Are Rare Events in AML and MDS and Are Associated with Complex Karyotype, TP53 Deletions and Very Poor Survival
    Haferlach, Claudia
    Grossmann, Vera
    Zenger, Melanie
    Kohlmann, Alexander
    Kern, Wolfgang
    Schnittger, Susanne
    Haferlach, Torsten
    BLOOD, 2011, 118 (21) : 1082 - 1082
12345